Earnings Releases·Nov 4, 2026, 7:03 AM ET

Q32 Bio — Third Quarter 2026 Earnings Summary

Cash and cash equivalents rose to $289.6 million as of September 30, 2026, from $48.3 million at year-end 2025, driven by a July 2026 public offering raising approximately $200.0 million, while venture debt was fully eliminated.
Net loss widened to $8.9 million ($0.26 per share) for the quarter ended September 30, 2026, compared to $7.4 million ($0.60 per share) in the prior year period, with total operating expenses increasing to $10.7 million from $7.6 million.
The company expects to initiate a registration-directed program for bempikibart in severe or very severe alopecia areata in the first half of 2027, subject to Q4 2026 regulatory discussions, with cash runway extending to Phase 3 topline results.
SIGNAL-AA Part B data showed a 35.3% mean reduction in SALT scores at Week 36 and robust durability during the 16-week off-drug period, supporting potential less frequent chronic maintenance dosing.
Management appointed new leadership including José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer in September 2026 to advance the registration program.